| Biomarker ID | 1245 |
| PMID | 24240687 |
| Year | 2013 |
| Biomarker | N-acetyl-L-aspartyl-L-glutamate peptidase-like 2 (NAALADL2 ) |
| Biomarker Basis | Expression Based |
| Biomolecule | Protein |
| Source | Tissue |
| Subjects | Humans |
| Regulation | Upregulated with High Gleason Score |
| Odds Ratio/Hazard Ratio/Relative Risk | NA |
| Effect on Pathways | Pathways include: SGK494 human kinase ARCHS4 coexpression, SCYL3 human kinase ARCHS4 coexpression, AURKC human kinase ARCHS4 coexpression, BMPR1B human kinase ARCHS4 coexpression, RPS6KA5 human kinase ARCHS4 coexpression |
| Experiment | Gleason Score 3 Vs 4 Vs 5 |
| Type of Biomarker | Prognostic |
| Cohort | 222 Benign Tissues along with 511 Prostate Cancer tissues were chosen for evaluation. Out of 511 cancerous tissue, 324 had Gleason Score (GS) 3, 168 had GS 4, 19 had GS 5 |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | p=0.028 |
| Method Used | Immunohistochemistry |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Validated on independent patient dataset |
| Technical Name | NAALADL2 |